HEADACHE头痛
HEADACHE(英文缩写 HEADACHE),ISSN 0017-8748,eISSN 1526-4610,中文译名:头痛 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.311 | Q1 |
| 2022 | 5.000 | Q1 |
| 2023 | 5.400 | Q1 |
| 2024 | 4.000 | Q1 |
| 2025 | 3.900 | Q2 |
HEADACHE 最新收录文献
-
1. Guest editorial on "Anti-CGRP treatments in women's health: Gaps and clinical evidence in menstrual migraine, pregnancy, lactation, and hormonal contraception".
1. 关于“抗CGRP治疗在女性健康中的应用：月经性偏头痛、妊娠、哺乳期及激素避孕中的差距与临床证据”的客座社论PMID:日期:2026-09-29该文献暂无摘要。
-
2. Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteers.
2. 外周给药fremanezumab在健康志愿者脑脊液中的分布与靶点结合情况PMID:日期:2026-09-23Our objective was to describe the distribution of fremanezumab to the cerebrospinal fluid (CSF) in healthy volunteers, and investigate its engagement and stabilization of its target, calcitonin gene-related peptide (CGRP). Fremanezumab is a CGRP-targeting monoclonal antibody approved for migraine prevention. Although the efficacy of peripherally administered monoclonal antibodies targeting CGRP, such as fremanezumab, has been established for the modulation of migraine, the extent of their distribution and target engagement within the central nervous system remains largely uncharacterized. This open-label, nonrandomized, parallel-group, no-treatment control, pharmacokinetics clinical trial was conducted between February 16, 2023, and April 1, 2023, in the United States. Healthy volunteers were assigned to one of five groups: Group 1 had no drug intervention, and Groups 2-5 received 900 mg fremanezumab intravenously. Blood and CSF samples were collected in Group 1 (n=6; baseline for blood and CSF control) and at 1 day (Group 2; n=5), 3 days (Group 3; n=5), 15 days (Group 4; n=5), and 30 days (Group 5; n=5) postinfusion. Additional blood sampling occurred in select groups at 15 min postinfusion and at predetermined time points up to 31 days postinfusion. Plasma and CSF samples were analyzed for fremanezumab and total CGRP using in-house immunoassays and high-performance liquid chromatography tandem-mass spectrometry. Mean (SD) plasma fremanezumab concentration peaked at the end of the 1-h intravenous infusion (333599.2 ng/mL [54658.6]) and decreased over the subsequent 31 days postinfusion (60482.3 ng/mL [10473.9]). CSF fremanezumab was detected at the earliest measured time point of 1 day postinfusion (mean [SD]=134.2 ng/mL [38.8]), increased at 15 days (243.6 ng/mL [189.4]), and remained sustained 30 days postinfusion (219.3 ng/mL [77.3]). Mean (SD) CSF-to-plasma concentration ratios increased over time, from 0.06% (0.02%) at 1 day to 0.36% (0.14%) at 30 days postinfusion. In plasma, sustained target engagement was demonstrated through the rapid rise of total CGRP, peaking at 15 days (mean [SD]=359.1 pg/mL [90.0]), and was sustained to 31 days postinfusion (260.5 pg/mL [43.0]). In the CSF, total CGRP was below detection limits for the control (Group 1) but was quantifiable at 1 day and sustained to 30 days postinfusion, with mean (SD) values ranging from 1.8-3.3 pg/mL (0.4-2.2). No severe or treatment-related adverse events were reported, and no participant withdrew due to an adverse event. The present findings suggest the rapid distribution of fremanezumab into the central nervous system after peripheral administration, and the persistent retention of fremanezumab and target engagement of CGRP in the CSF. Further studies are required to determine whether entry into the CSF and target engagement play a role in the clinical efficacy of fremanezumab observed in people with migraine. TV48125-PK-10183; EUPAS103511.
-
3. Self-administered medication devices' environmental waste consequences.
3. 自我给药装置的环境废弃物后果PMID:日期:2026-09-22该文献暂无摘要。
-
4. Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine-Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine.
PMID:日期:2026-09-22Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine-Diary (AIM-D) individual and activity limitation items, and complete improvement in AIM-D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 weeks of three phase 3 trials. Patient-reported functional outcomes are critical for assessing response to preventive migraine treatments, yet analyses of treatment effects on function at early timepoints are limited. Post hoc analyses assessed AIM-D data in three multicenter, placebo-controlled, double-blind, parallel-group, 12-week, randomized clinical trials in participants who received once-daily atogepant 60 mg or placebo: ADVANCE (episodic migraine [EM], 4-14 monthly migraine days [MMDs]; United States trial, December 14, 2018-June 19, 2020), ELEVATE (EM with prior failure to two to four classes of oral preventive migraine treatments; international trial, March 5, 2021-August 4, 2022), and PROGRESS (chronic migraine [CM]; ≥15 monthly headache days, including ≥8 MMDs; international trial, March 11, 2019-January 20, 2022). A separate activity limitation item was included in the daily eDiary to assess limitation of activity over the past 24 h. The percent change from baseline in each AIM-D item score and the activity limitation item score, and the proportions of participants achieving complete improvement (i.e., scores of zero) in AIM-D PDA or PI domain scores, were evaluated at weeks 1 through 4. A mixed model for repeated measures analysis compared least squares mean change from baseline in individual AIM-D items and activity limitation. A generalized linear mixed model compared the relative odds of achieving complete improvement. In ADVANCE, ELEVATE, and PROGRESS, participants treated with atogepant versus placebo generally had a greater reduction in the individual AIM-D item scores at weeks 1 (ADVANCE, p: <0.001-0.14; ELEVATE, all items p: <0.001; PROGRESS, p: <0.001-0.003), 2 (ADVANCE, p: <0.001-0.018; ELEVATE, p: <0.001-0.002; PROGRESS, p: 0.006-0.192), 3 (ADVANCE, p: <0.001-0.001; ELEVATE, p: <0.001-0.003; PROGRESS, p: 0.004-0.460), and 4 (ADVANCE, p: <0.001-0.028; ELEVATE, p: <0.001-0.050; PROGRESS, p: <0.001-0.067). At weeks 1 through 4, participants in ADVANCE and ELEVATE showed greater improvements in the activity limitation item scores with atogepant versus placebo (all p ≤ 0.001). There were higher odds of achieving complete improvement in the PDA and PI domain scores at weeks 1-4 with atogepant versus placebo across all trials (odds ratios: ADVANCE, 1.614-3.089; ELEVATE, 2.298-5.363; PROGRESS, 2.106-7.617). For preventive migraine treatment, atogepant once daily versus placebo was associated with early improvements in AIM-D individual and activity limitation items and with higher odds of achieving complete improvement for AIM-D domain scores in people with EM and CM, demonstrating early functional improvements across the migraine spectrum.
-
5. Patterns of head and neck pain and obstructive sleep apnea in women with macromastia: A cross-sectional analysis.
5. 巨乳症女性中头颈部疼痛与阻塞性睡眠呼吸暂停的模式：一项横断面分析PMID:日期:2026-09-22Symptomatic macromastia, or breast hypertrophy, is associated with musculoskeletal and neurological symptoms, including headache and neck pain. Though insurers list headache as an indication for breast reduction surgery, its relationship to specific headache phenotypes, neck pain disorders, and sleep-related disorders remains poorly understood. Our objectives were to evaluate the potential relationship between macromastia and chronic migraine, neck pain, cervical radiculopathy, occipital neuralgia, and obstructive sleep apnea (OSA), and to assess factors that influence the likelihood of treatment with reduction mammoplasty in an academic neurology practice. We conducted a retrospective cross-sectional study of women with and without macromastia by reviewing the charts of women with and without diagnosed macromastia (using the International Classification of Diseases, Tenth Revision code N62, hypertrophy of the breast) treated at an academic neurology practice from January 1, 2017, to December 31, 2024. Groups were matched on age, race-ethnicity, and body mass index (BMI) using propensity matching. In both groups, we analyzed diagnostic codes for chronic migraine, neck pain, cervical radiculopathy, occipital neuralgia, and OSA. The primary outcome was the prevalence of queried craniocervical pain disorders (e.g., chronic migraine, neck pain, occipital neuralgia, and cervical radiculopathy) in women with macromastia versus controls. For our secondary outcome, we examined the prevalence of OSA and rates of reduction mammoplasty in women with macromastia by type of craniocervical diagnostic code. We identified 347 women with macromastia and 340 matched controls. Postmatch differences remained for mean BMI (28.0 [SD = 6.7] vs. 26.5 [SD = 6.5] kg/m, standardized mean difference = 0.194), depression (48.4% vs. 29.7%, p < 0.001), and anxiety (57.3% vs. 32.9%, p < 0.001). After adjusting for BMI, demographics, and comorbid mood disorders, women with macromastia had significantly higher adjusted prevalence ratios (aPRs) for chronic migraine (aPR = 1.40; 95% CI = 1.16-1.68, p = 0.003), neck pain (aPR = 2.04; 95% CI = 1.65-2.53, p = 0.003), cervical radiculopathy (aPR = 2.38; 95% CI = 1.39-4.06, p = 0.026), and OSA (aPR = 1.54; 95% CI = 1.23-1.95, p = 0.003), but not occipital neuralgia (aPR = 1.54; 95% CI = 0.98-2.39, p = 0.054), compared to controls. Among women with macromastia, only those with neck pain were more likely to undergo reduction mammoplasty. In our retrospective, cross-sectional study, compared to women without macromastia, women with macromastia had a higher prevalence of chronic migraine, neck pain, cervical radiculopathy, and OSA. Women with macromastia and neck pain were more likely to have breast reduction surgery compared to women with macromastia without neck pain. Prospective, longitudinal studies are needed to clarify potential mechanisms driving macromastia's impact on migraine and other disorders and to assess the impact of macromastia treatment on headache outcomes.
-
7. Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross-sectional study.
7. 生殖阶段及向绝经过渡期间的激素治疗与偏头痛特征：一项横断面研究PMID:日期:2026-09-15Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. A cross-sectional study was conducted including females aged 18-60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen-only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross-checked with medical records and phone interviews. Age- and size-matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p-values > 0.05). Among females in the RS and regular menstrual cycles (n = 78), menstrually-related migraine was highly prevalent (67/78; 86%). In the RS group comparisons (n = 109), no differences according to HT use in migraine characteristics or menstruation-related symptoms were observed (all adjusted p-values > 0.05). Similarly, among females in the menopause transition (n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p-values > 0.05). In this real-world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually-related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.
-
8. Efficacy and cardiovascular safety of lasmiditan in patients with cardiovascular risk factors: A systematic review and meta-analysis with updated synthesis of triptan safety data.
8. 拉米地坦在具有心血管危险因素患者中的疗效与心血管安全性：一项系统评价和荟萃分析及曲普坦安全性数据的更新综合PMID:日期:2026-09-10This study was conducted to evaluate lasmiditan efficacy and cardiovascular (CV) safety in patients with CV risk factors, and provide an updated synthesis of observational evidence on long-term triptan-related CV outcomes. Approximately 20% of patients with migraine have CV contraindications to triptans. Lasmiditan, a selective 5-hydroxytryptamine (5-HT)F receptor agonist without vasoconstrictive properties, may offer a safer alternative to triptans for these patients. In this systematic review and meta-analysis, we systematically searched MEDLINE, Embase, Scopus, and Cochrane CENTRAL from inception to June 2025 following a retrospectively registered International Prospective Register of Systematic Reviews protocol (CRD420251208584). Primary outcomes were pain freedom at 2 h (efficacy; randomized controlled trials) and major adverse CV events (observational studies). Random-effects meta-analyses used odds ratios (ORs) for binary efficacy outcomes and hazard ratios for time-to-event safety data. Rare cardiac adverse events were analyzed using Peto ORs. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. Sixteen studies were included (six lasmiditan studies involving three randomized controlled trials [two phase 3 and one phase 2] enrolling 5126 participants, two post hoc analyses, one open-label extension, and 10 triptan CV safety studies). In the meta-analysis of three independent randomized controlled trials (eight dose-specific comparisons), lasmiditan significantly increased pain freedom at 2 h versus placebo (OR, 2.09; 95% confidence interval [CI], 1.66-2.63, p < 0.001; heterogeneity statistic (I) = 58.9%; GRADE: high certainty), with clear dose-dependent effects (50 mg OR ≈ 1.50; 100 mg OR ≈ 2.0; 200 mg OR ≈ 2.60; subgroup p < 0.001) and number needed to treat of 4.1-15.4. Most bothersome symptom freedom was similarly improved (OR, 1.79; 95% CI, 1.45-2.22, p < 0.001; I = 54.5%; GRADE: high certainty). Observational triptan safety data (14 comparisons from 10 studies) showed apparent CV protection (hazard ratio, 0.82; 95% CI, 0.73-0.92), although certainty was very low due to confounding by indication, inconsistency (I = 82.4%), and comparator indirectness. Cardiac treatment-emergent adverse events were rare with lasmiditan (<1%; Peto OR, 3.14; 95% CI, 1.10-8.98, based on 14 total events; GRADE: low certainty), with zero vasoconstrictive CV events across all trials. Common adverse events included dizziness (risk ratio [relative risk] [RR], 5.71), somnolence (RR, 2.68), and paresthesia (RR, 5.02), all dose-dependent. Lasmiditan demonstrated efficacy and favorable CV safety in CV-risk populations, with no vasoconstrictive events detected across 5126 participants. Common central nervous system adverse effects, particularly dizziness, require careful patient counseling. The recent voluntary market withdrawal of lasmiditan underscores the need for continued development and evaluation of non-vasoconstrictive acute migraine treatments for patients with CV contraindications to triptans.
-
9. Taking the history for suspected spinal cerebrospinal fluid leaks: A narrative review.
9. 疑似脊髓脑脊液漏的病史采集：叙述性综述PMID:日期:2026-09-10Spinal cerebrospinal fluid (CSF) leaks, including spontaneous intracranial hypotension, can be difficult to diagnose, requiring a high level of suspicion. Although the diagnosis is obvious in patients presenting with a new onset of coat hanger, orthostatic headaches that improve quickly in recumbence, the symptoms can be much more nuanced. Patients often experience misdiagnosis and delayed diagnosis, particularly if their brain imaging is negative, resulting in a severely impacted quality of life. Thus, it is incumbent for clinicians to be aware of both common and uncommon manifestations of spinal CSF leaks and to consider the possibility of a spinal CSF leak in patients with atypical symptoms, chronic migraine unresponsive to multiple treatments, or new daily persistent headache. This article provides a strategy for taking a medical history focused on CSF leak symptoms to help improve diagnostic accuracy and initiate appropriate testing. Examples and a list of topics to discuss are included.
-
10. Responding With Evidence and Access for Childhood Headaches (REACH) study: A comparative effectiveness trial of cognitive behavioral therapy monotherapy versus combined cognitive behavioral therapy-pharmacotherapy with amitriptyline for the prevention of childhood migraine-The study protocol.
PMID:日期:2026-09-08Migraine is one of the most common chronic health problems in children and adolescents, resulting in high levels of functional disability. Symptoms frequently persist into and impact the course of adulthood for affected individuals. Current practice recommendations include a combined therapy approach of preventive medication and cognitive behavioral therapy (CBT); however, no trials have systematically assessed whether a combined therapy approach is superior to a cognitive behavioral monotherapy intervention. The REACH (Responding With Evidence and Access for Childhood Headaches) trial will compare the impact of a CBT monotherapy to a combined treatment for prevention of migraine in youth, while addressing barriers to CBT access by utilizing a teletherapy approach. The study will include youth with migraine between the ages of 10 and 17 years from 15 sites across the United States, who will be randomly assigned to a CBT + pill (amitriptyline) group or CBT-alone group. Both groups will complete six sessions of telehealth CBT, as well as three booster sessions, over the course of 6 months. Participants will report on headache and migraine frequency and related disability via a daily headache diary before (28-day baseline), during, and after completion of the intervention (the last 28 days on the protocol). The CBT + pill group will also undergo a dose titration of clinically prescribed amitriptyline throughout the active treatment phase. Primary treatment outcomes are a ≥50% reduction in headache days and reduction in migraine-related disability (i.e., Pediatric Migraine Disability Assessment score ≤20). Findings of the REACH study may confirm current practice guidelines or provide evidence of comparable effectiveness of combined therapy and CBT monotherapy for prevention of migraine. This trial is designed to reinforce current guidelines for preventive headache management strategies in youth with migraine. The study will also advance knowledge by determining whether CBT alone, without the potential side effects of medication, is sufficient.